 - Product revenues of 476 million for full year 2020, 110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year - - Pipeline progress with CHS-1420 adalimumab biosimilar BLA accepted by FDA and FYB201 ranibizumab biosimilar BLA on track for mid-year filing - - Conference call and webcast today at 4:30 p.m. ET - 